GENELUX CORP

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for cancer treatment. The core of its research and development pipeline involves preclinical and clinical testing that relies on animal models. The company’s primary investigational product, Olvi-Vec, and its broader pipeline of next-generation oncolytic viruses are tested in animal studies to evaluate efficacy, biodistribution, and safety before advancing to human trials, a standard but exclusionary practice in the biopharmaceutical sector.

The specific evidence detailing the scale, nature, or oversight of Genelux's animal testing is not publicly available in the provided source materials from SEC filings. The company's regulatory disclosures focus on clinical development risks and compliance, not on preclinical research methodologies. Consequently, while the company's business model inherently involves animal exploitation for biomedical research, the narrative lacks the specific, material details—such as the number of animals used, the types of studies conducted, or any documented welfare violations—that typically substantiate an exclusion under this code. This record is based on the company's sector-standard practices rather than disclosed, company-specific evidence of its animal testing operations.